Group 1: Industry Overview - The agricultural chemical industry experienced significant demand recovery in 2022 due to the pandemic and geopolitical conflicts, but is now entering a destocking phase in 2023, leading to an oversupply situation in 2024 [4] - The domestic agricultural chemical industry shows regional and structural differentiation, with the eastern coastal areas focusing on automation and green upgrades, while the central and western regions are increasing production capacity [4] - There is a coexistence of structural oversupply and localized shortages in products like Acetochlor and Chlorantraniliprole due to sudden events [4] Group 2: Policy and Market Dynamics - The clearing of excess capacity in the agricultural chemical industry relies on market adjustments and macro-control policies, with some companies operating at low or negative margins prompting the exit of inefficient capacity [5][6] - Stricter safety and environmental regulations, along with government oversight, are expected to accelerate the elimination of outdated pesticide production capacity [5][6] Group 3: Product Pricing and Market Expectations - Currently, the market for core products like S-metolachlor and Ethoxysulfuron is under price pressure due to overall oversupply, but there is an expectation of price recovery in the second half of the year driven by international instability and increased demand [7] Group 4: Product Development and Strategy - The company is focusing on a "mature process + prior registration" strategy for new product development, with several differentiated high-efficiency components in the pipeline for global registration [8] - The product structure is being optimized by phasing out low-margin products and enhancing the proportion of fungicides and insecticides through technological upgrades, with a focus on high-value products [8]

Summary of Key Points Core Viewpoint - The company, Beijing Yingtai Jiahe Biotechnology Co., Ltd., announced the lifting of restrictions on the sale of 6,002,500 shares, which represents 0.49% of the total share capital [1]. Details of Restricted Stock Release - The total number of shares released from restrictions is 6,002,500 shares, accounting for 0.49% of the company's total share capital of 1,225,800,000 shares [2]. - The reasons for the release of restrictions include annual releases for directors, supervisors, and senior management, as well as releases due to the departure of these individuals [2]. Post-Release Share Capital Situation - After the release of restrictions, the total number of unrestricted shares is 1,207,582,500, which constitutes 98.51% of the total share capital [2]. - The total number of restricted shares remaining is 18,217,500, representing 1.49% of the total share capital [2]. Other Relevant Information - There are no outstanding commitments from the shareholders applying for the release of restrictions [2]. - There are no non-operational fund occupations by the shareholders applying for the release of restrictions [2]. - The company has confirmed that there are no violations or guarantees that could harm the company's interests related to the shareholders applying for the release [2].

股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 证券代码：920819 证券简称：颖泰生物 公告编号：2025-034 北京颖泰嘉和生物科技股份有限公司 A 董事、监事、高级管理人员每年解除限售 B 离职董事、监事、高级管理人员解除限售 C 自愿限售解除限售 D 限制性股票解除限售 E 公开发行前特定主体股票解除限售上市 一、本次股票解除限售数量总额为 6,002,500 股，占公司总股本 0.49%，可交易时间为 2025 年 5 月 27 日。 二、本次股票解除限售的明细情况及原因 单位：股 | | 股东 | 是否为控股 | 董事、监 | 本次 | | 本次解除限 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 本次解除限 | | 尚未解除限 | | 序 | 姓名 | 股东、实际 | 事、高级 | 解限 | | 售股数占公 | | | 号 | 或名 | 控制人或其 | 管理人员 | 售原 | 售登记 ...

北京颖泰嘉和生物科技股份有限公司 部分董事、高级管理人员增持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 | 增持主体姓名 | | 增持计划实施前 | 增持计划实 | | | 首次披露增持公告 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 或名称 | 增持主体身份 | 持股数量（股） | 施前 持股比例 | | | 的时间 | | | | | 陈伯阳 | 董事长 | 0 | 0% | 2024 | 年 | 9 | 月 | 13 | 日 | | 张海安 | 董事 | 0 | 0% | 2024 | 年 | 9 | 月 | 13 | 日 | | 刘晓亮 | 董事、总经理、董秘 | 0 | 0% | 2024 | 年 | 9 | 月 | 13 | 日 | | 杨玉松 | 高级管理人员 | 0 | 0% | 2024 | 年 | 9 | 月 | 13 | 日 | | 王榕 | 离任董事长 | 23, ...

证券代码：920819 证券简称：颖泰生物 公告编号：2025-031 北京颖泰嘉和生物科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 9 日 2.会议召开地点：公司会议室 3.会议召开方式：现场投票和网络投票相结合方式召开 4.会议召集人：董事会 5.会议主持人：陈伯阳 6.召开情况合法合规的说明： 本次股东会会议召开符合《公司法》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。本次会议召开不需 要相关部门批准。 （一）审议通过《董事会 2024 年度工作报告》 1.议案表决结果： 同意股数 738,753,372 股，占本次股东会有表决权股份总数的 99.9897%；反对股数 71,427 股，占本次股东会有表决权股份总数的 0.0097%；弃权股数 4,792 股，占本次股东会有表决权股份总数的 0.0006%。 （二）会议出席情况 出席和授权出席 ...

致：北京颖泰嘉和生物科技股份有限公司 北京市康达律师事务所 关于北京颖泰嘉和生物科技股份有限公司 2024 年年度股东会的法律意见书 康达股会字[2025]第 0135 号 北京市康达律师事务所（以下简称"本所"）接受北京颖泰嘉和生物科技股份 有限公司（以下简称"公司"）的委托，指派本所律师参加公司 2024 年年度股东 会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）、《北京证券交易所股票上市规则》和《北京颖泰嘉 和生物科技股份有限公司章程》（以下简称"《公司章程》"）等规定，就本次会 议的召集和召开程序、召集人和出席人员的资格、表决程序以及表决结果发表法 律意见。 关于本《法律意见书》，本所及本所律师谨作如下声明： 1．在本《法律意见书》中，本所及本所律师仅就本次会议的召集和召开程 序、召集人和出席人员的资格、表决程序以及表决结果进行核查和见证并发表法 律意见，不对本次会议的议案内容及其所涉及的事实和数据的完整性、真实性和 准确性发表意见。 1 北京市朝 ...

Group 1 - Over 3900 listed companies reported profits in Q1, indicating a strong start to the year, with major banks like ICBC, CCB, ABC, and BOC each exceeding 50 billion yuan in net profit [1] - BYD achieved revenue of 170.36 billion yuan in Q1, a year-on-year increase of 36.35%, with net profit reaching 9.155 billion yuan, up 100.38%, driven by strong growth in the new energy vehicle sector [1] - Sunshine Power reported revenue of 19.036 billion yuan, a 50.92% increase year-on-year, and net profit of 3.826 billion yuan, up 82.52%, with significant growth in inverter and energy storage segments [2] Group 2 - Cambrian Technology reported revenue of 1.111 billion yuan, a staggering increase of 4230.22% year-on-year, and net profit of 355 million yuan, marking a turnaround from losses [2] - Limin Co. turned a profit with net profit rising from a loss of 8.4917 million yuan to 108 million yuan, benefiting from price increases and higher sales in the domestic pesticide sector [2] - Companies like Jintan and Haopeng Technology are optimistic about 2025, focusing on high-margin markets and value customers, with expectations of steady profit growth through cost reduction and technological upgrades [3][4] Group 3 - Jintan plans to increase its old renovation business from 15% to 50% in 2024, while expanding overseas operations in regions like Southeast Asia and the Middle East [3] - GCL-Poly Energy aims to increase the share of energy service revenue to over 50% in the next five years, focusing on building a collaborative ecosystem around energy services [4] - Companies are generally confident about maintaining over 20% growth in revenue and profit by 2025, despite facing external uncertainties [3]

Core Viewpoint - The agricultural chemical industry is experiencing a recovery in the first quarter of 2024, with most companies reporting improved performance after a period of destocking in 2023 [1][5][6]. Group 1: Company Performance - As of April 28, 29 agricultural chemical companies have disclosed their Q1 reports, with 27 companies reporting profits and 16 showing year-on-year profit growth [1]. - Companies such as Lianhua Technology, Hunan Haili, and Lier Chemical reported net profit increases exceeding 100% year-on-year [2][3]. - Lianhua Technology's Q1 net profit grew over tenfold to 4971.56 million yuan, with a revenue of 15.1 billion yuan, marking a 3.02% increase [2]. - Hunan Haili achieved a revenue of 4.31 billion yuan, up 25.44%, and a net profit of 5661.02 million yuan, up 483.78% [3]. - Lier Chemical reported total revenue of 20.86 billion yuan, a 49.99% increase, and a net profit of 1.53 billion yuan, up 219.9% [3]. - Companies like Xianda Co. and Limin Co. turned losses into profits in Q1 due to increased sales and prices [4]. Group 2: Market Trends - The agricultural chemical market is entering its traditional peak season, with significant destocking observed since the beginning of the year [5][6]. - The market is showing signs of recovery, with an increase in terminal demand and replenishment in both domestic and foreign markets [6]. - The raw material price index for agricultural chemicals rose to 73.11 points, reflecting a 0.29% increase from the previous month [6]. - Industry experts express optimism for 2025, anticipating a stable recovery in the agricultural chemical sector [7].

Group 1: Financial Performance - The company's profit for 2024 is projected to be over negative 500 million, a significant drop from over 1 billion in 2022, indicating instability in operations [5] - The decline in profit is attributed to a combination of a downturn in the agricultural chemical industry and asset impairment losses [5] - The company aims to achieve profitability in 2025, with a positive trend observed in the first quarter [5][6] Group 2: Market Position and Product Range - The company produces over a hundred high-quality products across three main categories: herbicides, fungicides, and insecticides, with strong market competitiveness in certain herbicide classes [4] - The company has established a stable partnership with well-known domestic and international agricultural enterprises, which enhances its market position [6] Group 3: Risk Management and Financial Strategy - The company has implemented a comprehensive customer credit management system to mitigate accounts receivable risks, maintaining a low historical bad debt loss [5][6] - The company is actively adjusting its financing structure to control debt ratios and ensure stable cash flow, with sufficient bank credit available [6] Group 4: Industry Outlook - The agricultural chemical industry is expected to stabilize due to its weak cyclical nature and the rigid demand for agricultural production [10] - The company anticipates that the optimization of product structure and expansion into new application areas will create growth opportunities in the long term [10]

证券代码：833819 证券简称：颖泰生物 公告编号：2025-029 北京颖泰嘉和生物科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日 在 北 京 证 券 交 易 所 指 定 信 息 披 露 平 台 （http://www.bse.cn/）发布了《2024 年年度报告》（公告编号： 2025-014），为方便广大投资者更深入了解公司 2024 年年度经营业 绩的具体情况，加强与投资者的互动交流，公司拟召开 2024 年年 度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 4 月 25 日（星期五）15:00-17:00。 （二）会议召开地点 本次年度报告业绩说明会将采用网络方式召开，投资者可登录 全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年 度报告业绩说明会。 三、 参加人员 ...